Abstract
Objective To evaluate the efficacy of rotigotine in controlling the drooling of Parkinson's Disease (PD) patients. Patients and methods We assessed 7 PD patients (Hoehn and Yahr scale >2.5) with three different clinical scores (Drooling Severity and Frequency Scale − DSFS, Drooling Rating Scale – DRS and Sialorrhea Clinical Scale for PD – SCS) before and after 4 weeks of therapy. Statistical differences were analyzed with Wilcoxon signed-rank test. Results We observed that rotigotine significantly improves drooling as measured by the lowering of the three scores (p < 0.05). Conclusions Among non-motor symptoms of PD, drooling is one of the most embarrassing and disabling for patients. Current treatments are unsatisfactory and novel approaches are thus desirable. In this open-label pilot study we demonstrated on a small sample of patients that up to 4 mg/24 h of rotigotine, a non-ergolinic dopamine agonist with continuous transdermal delivery, may be helpful in the management of drooling in advanced PD.
| Original language | English |
|---|---|
| Pages (from-to) | 63-65 |
| Number of pages | 3 |
| Journal | Clinical Neurology and Neurosurgery |
| Volume | 156 |
| DOIs | |
| Publication status | Published - May 1 2017 |
Fingerprint
Keywords
- Deglutition and deglutition disorders
- Drooling
- Non motor symptoms
- Parkinson's Disease
- Rotigotine
- Sialorrhea
ASJC Scopus subject areas
- Surgery
- Clinical Neurology
Cite this
Rotigotine may control drooling in patients with Parkinson's Disease : Preliminary findings. / Schirinzi, Tommaso; Imbriani, Paola; D'Elia, Alessio; Di Lazzaro, Giulia; Mercuri, Nicola Biagio; Pisani, Antonio.
In: Clinical Neurology and Neurosurgery, Vol. 156, 01.05.2017, p. 63-65.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Rotigotine may control drooling in patients with Parkinson's Disease
T2 - Preliminary findings
AU - Schirinzi, Tommaso
AU - Imbriani, Paola
AU - D'Elia, Alessio
AU - Di Lazzaro, Giulia
AU - Mercuri, Nicola Biagio
AU - Pisani, Antonio
PY - 2017/5/1
Y1 - 2017/5/1
N2 - Objective To evaluate the efficacy of rotigotine in controlling the drooling of Parkinson's Disease (PD) patients. Patients and methods We assessed 7 PD patients (Hoehn and Yahr scale >2.5) with three different clinical scores (Drooling Severity and Frequency Scale − DSFS, Drooling Rating Scale – DRS and Sialorrhea Clinical Scale for PD – SCS) before and after 4 weeks of therapy. Statistical differences were analyzed with Wilcoxon signed-rank test. Results We observed that rotigotine significantly improves drooling as measured by the lowering of the three scores (p < 0.05). Conclusions Among non-motor symptoms of PD, drooling is one of the most embarrassing and disabling for patients. Current treatments are unsatisfactory and novel approaches are thus desirable. In this open-label pilot study we demonstrated on a small sample of patients that up to 4 mg/24 h of rotigotine, a non-ergolinic dopamine agonist with continuous transdermal delivery, may be helpful in the management of drooling in advanced PD.
AB - Objective To evaluate the efficacy of rotigotine in controlling the drooling of Parkinson's Disease (PD) patients. Patients and methods We assessed 7 PD patients (Hoehn and Yahr scale >2.5) with three different clinical scores (Drooling Severity and Frequency Scale − DSFS, Drooling Rating Scale – DRS and Sialorrhea Clinical Scale for PD – SCS) before and after 4 weeks of therapy. Statistical differences were analyzed with Wilcoxon signed-rank test. Results We observed that rotigotine significantly improves drooling as measured by the lowering of the three scores (p < 0.05). Conclusions Among non-motor symptoms of PD, drooling is one of the most embarrassing and disabling for patients. Current treatments are unsatisfactory and novel approaches are thus desirable. In this open-label pilot study we demonstrated on a small sample of patients that up to 4 mg/24 h of rotigotine, a non-ergolinic dopamine agonist with continuous transdermal delivery, may be helpful in the management of drooling in advanced PD.
KW - Deglutition and deglutition disorders
KW - Drooling
KW - Non motor symptoms
KW - Parkinson's Disease
KW - Rotigotine
KW - Sialorrhea
UR - http://www.scopus.com/inward/record.url?scp=85015872736&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85015872736&partnerID=8YFLogxK
U2 - 10.1016/j.clineuro.2017.03.012
DO - 10.1016/j.clineuro.2017.03.012
M3 - Article
AN - SCOPUS:85015872736
VL - 156
SP - 63
EP - 65
JO - Clinical Neurology and Neurosurgery
JF - Clinical Neurology and Neurosurgery
SN - 0303-8467
ER -